Experiment: 6H8C

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.6 mM [U-99% 13C; U-99% 15N] GABARAPL2, 1.0 mM No Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 600 MHz 600
2	2D 1H-15N HSQC	1.0 mM No GABARAPL2, 0.6 mM [U-99% 13C; U-99% 15N] Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 600 MHz 600
3	2D 1H-13C HSQC	0.6 mM [U-99% 13C; U-99% 15N] GABARAPL2, 1.0 mM No Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 950 MHz 950
4	2D 1H-13C HSQC	1.0 mM No GABARAPL2, 0.6 mM [U-99% 13C; U-99% 15N] Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 950 MHz 950
5	3D HNCACB	0.6 mM [U-99% 13C; U-99% 15N] GABARAPL2, 1.0 mM No Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 800 MHz 800
6	3D HNCACB	1.0 mM No GABARAPL2, 0.6 mM [U-99% 13C; U-99% 15N] Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 800 MHz 800
8	3D (HCA)CO(CA)NH	0.6 mM [U-99% 13C; U-99% 15N] GABARAPL2, 1.0 mM No Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 700 MHz 700
7	3D (HCA)CO(CA)NH	1.0 mM No GABARAPL2, 0.6 mM [U-99% 13C; U-99% 15N] Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 700 MHz 700
14	3D H(CC)(CO)NH-TOCSY	0.6 mM [U-99% 13C; U-99% 15N] GABARAPL2, 1.0 mM No Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 900 MHz 900
13	3D H(CC)(CO)NH-TOCSY	1.0 mM No GABARAPL2, 0.6 mM [U-99% 13C; U-99% 15N] Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 900 MHz 900
12	3D (H)CC(CO)NH-TOCSY	0.6 mM [U-99% 13C; U-99% 15N] GABARAPL2, 1.0 mM No Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 900 MHz 900
11	3D (H)CC(CO)NH-TOCSY	1.0 mM No GABARAPL2, 0.6 mM [U-99% 13C; U-99% 15N] Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 900 MHz 900
10	3D 1H-15N NOESY	0.6 mM [U-99% 13C; U-99% 15N] GABARAPL2, 1.0 mM No Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 950 MHz 950
9	3D 1H-15N NOESY	1.0 mM No GABARAPL2, 0.6 mM [U-99% 13C; U-99% 15N] Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 950 MHz 950
16	3D 1H-13C NOESY	0.6 mM [U-99% 13C; U-99% 15N] GABARAPL2, 1.0 mM No Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 950 MHz 950
18	3D 1H-13C NOESY	1.0 mM No GABARAPL2, 0.6 mM [U-99% 13C; U-99% 15N] Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 950 MHz 950
17	3D NOESY-[13C,1H]-HSQC 13C/15N filtered in F1	0.6 mM [U-99% 13C; U-99% 15N] GABARAPL2, 1.0 mM No Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 900 MHz 900
15	3D NOESY-[13C,1H]-HSQC 13C/15N filtered in F1	1.0 mM No GABARAPL2, 0.6 mM [U-99% 13C; U-99% 15N] Ubiquitin-like modifier-activating enzyme 5 (UBA5) LIR motif, 50 mM No sodium phosphate, 100 mM No sodium chloride, 4.6 mM No sodium azide	95% H2O/5% D2O	100 mM	7.0	AMBIENT atm	298	Bruker Bruker Avance 900 MHz 900

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	Bruker Avance 950 MHz	950
2	Bruker	Bruker Avance 900 MHz	900
3	Bruker	Bruker Avance 800 MHz	800
4	Bruker	Bruker Avance 700 MHz	700
5	Bruker	Bruker Avance 600 MHz	600
6	Bruker	Bruker Avance 500 MHz	500

NMR Refinement
Method	Details	Software
torsion angle dynamics	AMBER94	OPAL

NMR Ensemble Information
Conformer Selection Criteria	target function
Conformers Calculated Total Number	200
Conformers Submitted Total Number	20
Representative Model	1 (closest to the average)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	collection	TopSpin	3.1	Bruker Biospin
2	chemical shift assignment	Sparky	1.114	Goddard
3	peak picking	CYANA	3.97	Guntert, Mumenthaler and Wuthrich
4	structure calculation	CYANA	3.97	Guntert, Mumenthaler and Wuthrich
5	refinement	OPAL		Luginbuhl, Guntert, Billeter and Wuthrich

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.